Peptide rules
Can a doctor prescribe Epitalon?
Short answer
As of FDA's list updated May 14, 2026, Epitalon is not on FDA's list of ingredients compounding pharmacies may use while FDA reviews them. FDA had placed it in Category 2 (significant safety risks); the nomination was later withdrawn, so it does not appear in any category. Not right now: it is not on FDA's current list of ingredients a compounding pharmacy may use.
Also called: Epithalon, Epithalone.
Where FDA's list stands
As of FDA's list updated May 14, 2026, Epitalon is not on FDA's list of ingredients compounding pharmacies may use while FDA reviews them. FDA had placed it in Category 2 (significant safety risks); the nomination was later withdrawn, so it does not appear in any category.
FDA sorts ingredients it is reviewing for pharmacy compounding into three groups. This one was first placed in Category 2 (significant safety risks), then the person who asked FDA to review it withdrew that request. FDA's current list does not place a withdrawn ingredient in any category, which is different from being cleared or banned: it simply is not part of this review process right now.
The July 2026 advisory committee review
July 24, 2026
On July 24, 2026, FDA's Pharmacy Compounding Advisory Committee discussed Epitalon. NCPA, July 31, 2026 reports the committee voted to recommend adding it to the list pharmacies may use. The vote is advice to FDA, not binding, and FDA has not issued a final rule, so pharmacies may not compound it under this process until then.
What this means if you're looking for a clinician
Ask any clinic which peptides it prescribes, whether each one is FDA-approved or compounded, and which state-licensed pharmacy fills it. A clinic that prescribes Epitalon should be able to tell you where its pharmacy sources the ingredient from.
Find a licensed clinician for my state Online peptide doctors
Sources
FDA: Certain bulk drug substances for use in compounding that may present significant safety risks
“This list of bulk drug substances previously in category 2 of the interim policies were withdrawn by the nominators.” Source
FDA, meeting page updated August 6, 2026
“Epitalon” Source
NCPA, July 31, 2026
“PCAC's votes are recommendations and are not binding on the FDA. ... Pharmacies will not be permitted to compound them until the final rulemaking is in place.” Source
Frequently asked questions
Can a doctor prescribe Epitalon?
As of FDA's list updated May 14, 2026, Epitalon is not on FDA's list of ingredients compounding pharmacies may use while FDA reviews them. FDA had placed it in Category 2 (significant safety risks); the nomination was later withdrawn, so it does not appear in any category. Not right now: it is not on FDA's current list of ingredients a compounding pharmacy may use.
What does "Nominated, then withdrawn" mean?
FDA had sorted it into a review category, then the nomination was withdrawn, so it is not in any category on FDA's current list.
Did FDA's advisory committee review Epitalon in July 2026?
On July 24, 2026, FDA's Pharmacy Compounding Advisory Committee discussed Epitalon. NCPA, July 31, 2026 reports the committee voted to recommend adding it to the list pharmacies may use. The vote is advice to FDA, not binding, and FDA has not issued a final rule, so pharmacies may not compound it under this process until then.
Is this legal or medical advice?
No. This page explains public FDA information in plain words. It is not legal or medical advice, and rules can change. Talk to a licensed clinician and check the linked FDA pages yourself.
This page explains public FDA information in plain words. It is not legal or medical advice.